HER2 Vaccine Candidate Meet Phase 1b Study An Australian biotech company stated its Human Epidermal Growth Factor Receptor 2 (HER2) vaccine candidate, HER-Vaxx, successfully finished its phase 1b c...
In a groundbreaking clinical trial, a 66-year-old Ohio woman became the first patient to become cancer free through the CAR T Cell Therapy. In August this year, Denise Kennan had participated in the cancer treatment trial at the Seidman Cancer Center in University Hospitals of Cleveland; following which 30 days late...
Find More
In what could be regarded as a precursor to a new mode of cancer diagnosis, an artificial intelligence based tool, developed at the Osaka University in Japan, can precisely differentiate between different cancer cells, paving the way for automated determination of appropriate individualized cancer treatments. As a m...
Find More
Lilly remunerates AC Immune USD 81 Million for preclinical Alzheimer’s drug Eli Lilly has remunerated USD 81 million upfront for the global rights to AC Immune’s tau aggregation inhibitors in Alzheimer’s disease. The agreement provides Lilly ownership of a small molecule that has prevented tau aggregation in preclin...
Find More
Chinese scientist - He Jiankui’s extraordinary claim regarding making the first babies — twin girls — with edited genomes astonished the world. Among researchers’ principal concerns are the potential effects of the genetic alterations on the health of girls. He, a genome-editing researcher at the Southern University...
Find More
Axovant tips nelotanserin from small molecule R&D Axovant has stopped nelotanserin development after it missed the primary endpoint in a phase 2 trial in patients with Lewy body dementia. The dull data compelled Axovant to miss the drug and finish its pivot from small molecules to gene therapies. The parent comp...
Find More
Gold nanoparticles may soon turn out to be a Prostate cancer treatment option. Apparently, there are certain risks associated with conventional cancer treatments such as uncontrolled bleeding, fatal blood clots and dangerous reactions to the anaesthetic, among others. To relieve patients from such risks, a new clini...
Find More
The world of cancer cells is bewildering, very difficult in understanding. The behaviour of cancer cells is not only complex but also intriguing. Research has been unfolding mystery after mystery of the complex world of cancer cells, shedding more and more light into the mysterious nature of cancer cells. In a new t...
Find More
Roche signs Icagen in neuro drug discovery deal worth up to USD 274 Million Roche and Icagen have signed a licensing and collaboration deal regarding ion channel modulators for neurological disorders. Icagen receives up to USD 274 million in development and commercial milestones. The duo will work on small molecules...
Find More
[caption id="attachment_3727" align="aligncenter" width="2322"] FDA[/caption]
Find More
Progressive Supranuclear Palsy (PSP) is a rare progressive disorder resulting from damage that occur.....
Find More
Systemic Lupus Erythematosus (SLE) is an autoimmune disease where the immune system of the body mist.....
Find More
In the present scenario, the 3-D printing and bioprinting technology in the medical devices industry.....
Find More
A rare glomerular kidney-scarring disease, Focal Segmental Glomerulosclerosis (FSGS) is a disease wi.....
Find More
Celiac disease is an autoimmune disorder against the gluten consumed that creates toxins, thereby, d.....
Find More
T cell Lymphoma (TCL) is cancer that develops in the T-lymphocytes. T-cell Lymphomas are majorly cla.....
Find More-Agonist.png "Toll-like Receptors Agonist")
The American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.
